Objectivity Squared’s Anika Therapeutics ANIK Stock Holding History

Objectivity Squared’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-31,575	Closed	-$303K	–	56
2025 Q4	$303K	Buy	+31,575	New	+$302K	0.17%	47

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Objectivity Squared's ANIK Position: Q1 2026 in Review

Objectivity Squared sold out of Anika Therapeutics (ANIK) in Q1 2026, closing a stake of 31,575 shares — an estimated $303K sold.

Objectivity Squared first reported a position in ANIK in Q4 2025 and held it in 1 quarter. The position peaked at $303K in Q4 2025. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

Objectivity Squared reported no remaining Anika Therapeutics position as of Q1 2026 after selling out during the quarter.
Objectivity Squared sold 31,575 Anika Therapeutics shares in Q1 2026, an estimated $303K.
Objectivity Squared first reported a position in Anika Therapeutics in Q4 2025 and held it in 1 quarter.
Objectivity Squared's Anika Therapeutics position peaked at $303K in Q4 2025.
130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Objectivity Squared's 13F filing for Q1 2026, filed 13 May 2026.